Modeled reductions in COPD exacerbation rates, mortality, and related medical costs due to increased SITT adoption: PROMETHEUS Italy
Assuming RCTs effects and adherence translate to clinical practice, our model shows that higher than current SITT use in the Italian COPD population may lead to lower mortality rates and exacerbations, ensuring a substantial savings in associated medical costs. The results of this modeling study could provide rationale to modify existing practices on SITT prescribing with the aim of alleviating the burden of COPD.
Authors
- Melissa Caplen
- Jennifer Carioto
- Alberto Papi (ORCID: https://orcid.org/0000-0002-6924-4500)
- John Bell (ORCID: https://orcid.org/0000-0001-9307-1235)
- Bruce Pyenson (ORCID: https://orcid.org/0000-0003-0416-9391)
- Paula Rosa
- Prachi Bhatt
- Pierachille Santus (ORCID: https://orcid.org/0000-0003-3462-8253)
- Bianca Oresta
- Davide Finocchiaro
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of Ferrara (IT)
- AstraZeneca (Italy) (IT)
- ASST Fatebenefratelli Sacco (IT)
- Milliman (United States) (US)
Publication Details
- Journal
- Respiratory Research
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1186/s12931-025-03358-8
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca